Q-omics provides the consensus-scored IRF2BPL profile across patient tissues and cancer cell-line models. IRF2BPL expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IRF2BPL is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IRF2BPL protein abundance shows 25,165 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where IRF2BPL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IRF2BPL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IRF2BPL survival associations across molecular data types. IRF2BPL RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IRF2BPL RNA expression–survival associations across cancer types. High IRF2BPL expression shows unfavorable associations in UVM, LAML and LGG, but favorable associations in MESO, UCS and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify UVM as the clearest survival context for IRF2BPL RNA expression.
This table summarizes IRF2BPL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IRF2BPL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IRF2BPL shows lower tumor expression in KIRC, KICH, KIRP and UCEC and higher tumor expression in HNSC and CHOL. The KIRC box plot shows higher IRF2BPL RNA expression in normal versus tumor tissue (log2 FC = −1.521, t-test p < 0.001).
This table shows molecular features associated with IRF2BPL in patient tissues and cancer cell lines. In patient samples, IRF2BPL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IRF2BPL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
